Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients

Factors associated with response

M. K. Jain, L. Comanor, A. Clinton White, P. Kipnis, C. Elkin, K. Leung, A. Ocampo, N. Attar, Philip Keiser, W. M. Lee

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

As therapy for human immunodeficiency virus (HIV) infection evolves, optimizing hepatitis B virus (HBV) treatment and identifying factors that impact its response in the HIV/HBV-coinfected population is critical. We identified retrospectively 45 HBV/HIV-coinfected patients with detectable HBV DNA by the Bayer VERSANT® HBV 3.0 bDNA assay (limit of quantification 2000 copies/mL) at baseline and/or year 1 of therapy. Patients were divided into three groups based on the active HBV agent in their antiretroviral regimen: group 1 (n = 15) received lamivudine; group 2 (n = 10), lamivudine plus tenofovir and group 3 (n = 20), lamivudine followed by lamivudine plus tenofovir. HBV genotypes and resistance profiles were determined by the Bayer Trugene® HBV 1.0 assay. More patients in group 2 achieved HBV DNA suppression below 2000 copies/mL (80%), loss of HBe antigen (HBeAg) (40%) and loss of HBeAg and gain of anti-HBe (20%) than did patients in group 1 or 3. More patients with HBV genotype A, achieved HBV DNA suppression <2000 copies/mL than did patients with non-A genotypes [74% (26/35) vs 20% (2/10)], respectively (P = 0.003). Risk for virological nonresponse was significant in those with non-A genotypes [odds ratio (OR) 11.1; 95% CI: 2.0-50], previous HIV therapy (OR 6.5; 95% CI: 1.2-35) and <90% compliance (OR 3.7; 95% CI: 0.99-14.3). Simultaneous therapy with lamivudine/tenofovir suppresses HBV DNA more effectively than lamivudine or tenofovir added to lamivudine. More patients infected with HBV genotype A responded than the non-A patients, regardless of therapeutic regimen, compliance or prior HIV therapy.

Original languageEnglish (US)
Pages (from-to)176-182
Number of pages7
JournalJournal of Viral Hepatitis
Volume14
Issue number3
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Tenofovir
Lamivudine
Hepatitis B
Hepatitis B virus
HIV
Genotype
Therapeutics
DNA
Odds Ratio
Compliance
Branched DNA Signal Amplification Assay

Keywords

  • HBV genotype
  • HIV/HBV coinfection
  • Lamivudine
  • Tenofovir
  • Therapeutic response

ASJC Scopus subject areas

  • Hepatology
  • Virology

Cite this

Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients : Factors associated with response. / Jain, M. K.; Comanor, L.; White, A. Clinton; Kipnis, P.; Elkin, C.; Leung, K.; Ocampo, A.; Attar, N.; Keiser, Philip; Lee, W. M.

In: Journal of Viral Hepatitis, Vol. 14, No. 3, 03.2007, p. 176-182.

Research output: Contribution to journalArticle

Jain, M. K. ; Comanor, L. ; White, A. Clinton ; Kipnis, P. ; Elkin, C. ; Leung, K. ; Ocampo, A. ; Attar, N. ; Keiser, Philip ; Lee, W. M. / Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients : Factors associated with response. In: Journal of Viral Hepatitis. 2007 ; Vol. 14, No. 3. pp. 176-182.
@article{db1b5e3784d7421cb9996cfd9804e896,
title = "Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: Factors associated with response",
abstract = "As therapy for human immunodeficiency virus (HIV) infection evolves, optimizing hepatitis B virus (HBV) treatment and identifying factors that impact its response in the HIV/HBV-coinfected population is critical. We identified retrospectively 45 HBV/HIV-coinfected patients with detectable HBV DNA by the Bayer VERSANT{\circledR} HBV 3.0 bDNA assay (limit of quantification 2000 copies/mL) at baseline and/or year 1 of therapy. Patients were divided into three groups based on the active HBV agent in their antiretroviral regimen: group 1 (n = 15) received lamivudine; group 2 (n = 10), lamivudine plus tenofovir and group 3 (n = 20), lamivudine followed by lamivudine plus tenofovir. HBV genotypes and resistance profiles were determined by the Bayer Trugene{\circledR} HBV 1.0 assay. More patients in group 2 achieved HBV DNA suppression below 2000 copies/mL (80{\%}), loss of HBe antigen (HBeAg) (40{\%}) and loss of HBeAg and gain of anti-HBe (20{\%}) than did patients in group 1 or 3. More patients with HBV genotype A, achieved HBV DNA suppression <2000 copies/mL than did patients with non-A genotypes [74{\%} (26/35) vs 20{\%} (2/10)], respectively (P = 0.003). Risk for virological nonresponse was significant in those with non-A genotypes [odds ratio (OR) 11.1; 95{\%} CI: 2.0-50], previous HIV therapy (OR 6.5; 95{\%} CI: 1.2-35) and <90{\%} compliance (OR 3.7; 95{\%} CI: 0.99-14.3). Simultaneous therapy with lamivudine/tenofovir suppresses HBV DNA more effectively than lamivudine or tenofovir added to lamivudine. More patients infected with HBV genotype A responded than the non-A patients, regardless of therapeutic regimen, compliance or prior HIV therapy.",
keywords = "HBV genotype, HIV/HBV coinfection, Lamivudine, Tenofovir, Therapeutic response",
author = "Jain, {M. K.} and L. Comanor and White, {A. Clinton} and P. Kipnis and C. Elkin and K. Leung and A. Ocampo and N. Attar and Philip Keiser and Lee, {W. M.}",
year = "2007",
month = "3",
doi = "10.1111/j.1365-2893.2006.00797.x",
language = "English (US)",
volume = "14",
pages = "176--182",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients

T2 - Factors associated with response

AU - Jain, M. K.

AU - Comanor, L.

AU - White, A. Clinton

AU - Kipnis, P.

AU - Elkin, C.

AU - Leung, K.

AU - Ocampo, A.

AU - Attar, N.

AU - Keiser, Philip

AU - Lee, W. M.

PY - 2007/3

Y1 - 2007/3

N2 - As therapy for human immunodeficiency virus (HIV) infection evolves, optimizing hepatitis B virus (HBV) treatment and identifying factors that impact its response in the HIV/HBV-coinfected population is critical. We identified retrospectively 45 HBV/HIV-coinfected patients with detectable HBV DNA by the Bayer VERSANT® HBV 3.0 bDNA assay (limit of quantification 2000 copies/mL) at baseline and/or year 1 of therapy. Patients were divided into three groups based on the active HBV agent in their antiretroviral regimen: group 1 (n = 15) received lamivudine; group 2 (n = 10), lamivudine plus tenofovir and group 3 (n = 20), lamivudine followed by lamivudine plus tenofovir. HBV genotypes and resistance profiles were determined by the Bayer Trugene® HBV 1.0 assay. More patients in group 2 achieved HBV DNA suppression below 2000 copies/mL (80%), loss of HBe antigen (HBeAg) (40%) and loss of HBeAg and gain of anti-HBe (20%) than did patients in group 1 or 3. More patients with HBV genotype A, achieved HBV DNA suppression <2000 copies/mL than did patients with non-A genotypes [74% (26/35) vs 20% (2/10)], respectively (P = 0.003). Risk for virological nonresponse was significant in those with non-A genotypes [odds ratio (OR) 11.1; 95% CI: 2.0-50], previous HIV therapy (OR 6.5; 95% CI: 1.2-35) and <90% compliance (OR 3.7; 95% CI: 0.99-14.3). Simultaneous therapy with lamivudine/tenofovir suppresses HBV DNA more effectively than lamivudine or tenofovir added to lamivudine. More patients infected with HBV genotype A responded than the non-A patients, regardless of therapeutic regimen, compliance or prior HIV therapy.

AB - As therapy for human immunodeficiency virus (HIV) infection evolves, optimizing hepatitis B virus (HBV) treatment and identifying factors that impact its response in the HIV/HBV-coinfected population is critical. We identified retrospectively 45 HBV/HIV-coinfected patients with detectable HBV DNA by the Bayer VERSANT® HBV 3.0 bDNA assay (limit of quantification 2000 copies/mL) at baseline and/or year 1 of therapy. Patients were divided into three groups based on the active HBV agent in their antiretroviral regimen: group 1 (n = 15) received lamivudine; group 2 (n = 10), lamivudine plus tenofovir and group 3 (n = 20), lamivudine followed by lamivudine plus tenofovir. HBV genotypes and resistance profiles were determined by the Bayer Trugene® HBV 1.0 assay. More patients in group 2 achieved HBV DNA suppression below 2000 copies/mL (80%), loss of HBe antigen (HBeAg) (40%) and loss of HBeAg and gain of anti-HBe (20%) than did patients in group 1 or 3. More patients with HBV genotype A, achieved HBV DNA suppression <2000 copies/mL than did patients with non-A genotypes [74% (26/35) vs 20% (2/10)], respectively (P = 0.003). Risk for virological nonresponse was significant in those with non-A genotypes [odds ratio (OR) 11.1; 95% CI: 2.0-50], previous HIV therapy (OR 6.5; 95% CI: 1.2-35) and <90% compliance (OR 3.7; 95% CI: 0.99-14.3). Simultaneous therapy with lamivudine/tenofovir suppresses HBV DNA more effectively than lamivudine or tenofovir added to lamivudine. More patients infected with HBV genotype A responded than the non-A patients, regardless of therapeutic regimen, compliance or prior HIV therapy.

KW - HBV genotype

KW - HIV/HBV coinfection

KW - Lamivudine

KW - Tenofovir

KW - Therapeutic response

UR - http://www.scopus.com/inward/record.url?scp=33846997179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846997179&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2893.2006.00797.x

DO - 10.1111/j.1365-2893.2006.00797.x

M3 - Article

VL - 14

SP - 176

EP - 182

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - 3

ER -